Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 3 recruiting now early-phase tilt small index

Shwachman-Diamond Syndrome: early-phase trial registry

3 of 4 indexed Shwachman-Diamond Syndrome trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #4,115 of 28,707 conditions by registered trial count.

4 US clinical trials · 3 currently recruiting · #4,115 of 28,707 conditions by registered trial count

Shwachman-Diamond Syndrome: 4 US clinical trials tracked, 3 recruiting.

Shwachman-Diamond Syndrome is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Shwachman-Diamond Syndrome Alliance, running 1 of these trials.

Enrollment posture brief

Registry condition shwachman-diamond-syndrome

OPEN 3 | RECR 75% | LATE 0 | EARLY 1 | RANK #4115 | SPON 1

Nearest open-share peer: Activity, Motor (75% recruiting · 8 trials)

Ablation80%ACL Reconstruction80%Shwachman-Diamond Syndro (th…75%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Shwachman-Diamond Syndrome

Shwachman-Diamond Syndrome lists 3 open slots (75% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Shwachman-Diamond Syndrome on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Shwachman-Diamond Syndrome is recruiting above its size-band peers.

    3 of 4 indexed trials (75%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 21

Phase Distribution

PhaseTrial count
Phase 2 1

Named interventions

Most-linked intervention names on Shwachman-Diamond Syndrome records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Campath, Fludarabine, Cyclophosphamide Drug
1 trials
Busulfan, Cyclophosphamide, ATG, GCSF Drug
1 trials
Busulfan, Fludarabine, ATG, TLI Drug
1 trials
Stem cell infusion Procedure
1 trials
Total Body Irradiation Radiation
1 trials

US sites by state

Facility locations filed on Shwachman-Diamond Syndrome trials. A trial with sites in several states counts in each.

Massachusetts 2 trials
Ohio 1 trials
Minnesota 1 trials
Maryland 1 trials
Colorado 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Shwachman-Diamond Syndrome page

4 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Shwachman-Diamond Syndrome condition card totals 4 registered trials; most-linked intervention Campath, Fludarabine, Cyclophosphamide; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.